Implications of the 2026 Cardiovascular-Kidney-Metabolic Syndrome Guideline for GLP-1 Receptor Agonist and SGLT2 Inhibitor Eligibility Among US Adults
Background The 2026 cardiovascular-kidney-metabolic (CKM) syndrome guideline broadens recommendations for glucagon-like peptide-1 receptor agonists (GLP-1R